Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Gross Profit | -7.3M | 4.9% |
| Cost of Revenue | 7.3M | 4.9% |
| Operating expense | 23M | 3.5% |
| Net Income | -21M | 3.8% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 244M | 2.4% |
| Total Liabilities | 64M | 24.1% |
| Total Equity | 180M | 9.3% |
| Shares Outstanding | 9.3M | 0.4% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -16M | 10.3% |
| Cash from investing | -13M | 87.7% |
| Cash from financing | 730,000 | 98.9% |
EPS
Financial Highlights for Korro Bio in Q3 '24
Gross Profit stood at -7.3M, marking a -4.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 7.3M, a 4.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 23M, showing a -3.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -21M, showing a 3.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
Korro Bio faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
